Management of Violence and Aggression in Emergency Environment; a Narrative Review of 200 Related Articles
-
Maryam Ziaei
,
Ali Massoudifar
,
Ali Rajabpour-Sanati
,
Ali-Mohammad Pourbagher-Shahri
,
Ali Abdolrazaghnejad
Abstract
Context: The aim of this study is to reviewing various approaches for dealing with agitated patients in emergency department (ED) including of chemical and physical restraint methods. Evidence acquisition: This review was conducted by searching “Violence,” “Aggression,” and “workplace violence” keywords in these databases: PubMed, Scopus, EmBase, ScienceDirect, Cochrane Database, and Google Scholar. In addition to using keywords for finding the papers, the related article capability was used to find more papers. From the found papers, published papers from 2005 to 2018 were chosen to enter the paper pool for further review. Results: Ultimately, 200 papers were used in this paper to conduct a comprehensive review regarding violence management in ED. The results were categorized as prevention, verbal methods, pharmacological interventions and physical restraint. Conclusion: In this study various methods of chemical and physical restraint methods were reviewed so an emergency medicine physician be aware of various available choices in different clinical situations for agitated patients.
1. American Association of Occupational Health Nurses Unveils 2005 Public Policy Platform [Available from: https://www.ehstoday.com/news/ehs_imp_37420.
2. Zampieron A, Galeazzo M, Turra S, Buja A. Perceived aggression towards nurses: study in two Italian health institutions. J Clin Nurs. 2010;19(15-16):2329-41.
3. Alameddine M, Kazzi A, El-Jardali F, Dimassi H, Maalouf S. Occupational violence at Lebanese emergency departments: prevalence, characteristics and associated factors. J Occup Health. 2011;53(6):455-64.
4. Esmaeilpour M, Salsali M, Ahmadi F. Workplace violence against Iranian nurses working in emergency departments. Int Nurs Rev. 2011;58(1):130-7.
5. Rafati Rahimzadeh M, Zabihi A, Hosseini S. Verbal and physical violence on nurses in hospitals of Babol University of Medical Sciences. Hayat. 2011;17(2):5-11.
6. Hilliar K. Police-recorded assaults on hospital premises in New South Wales: 1996-2006. Crim Just Bull. 2008;16:1-12
7. Lau JB, Magarey J, McCutcheon H. Violence in the emergency department: a literature review. Australas Emerg Nurs J. 2004;7(2):27-37.
8. Nurses and Violence in the Workplace [Available from: https://www.ausmed.com/articles/nurses-and-violence-in-the-workplace/.
9. Ferns T. Violence in the accident and emergency department--an international perspective. Accid Emerg Nurs. 2005;13(3):180-5.
10. Kindy D, Petersen S, Parkhurst D. Perilous work: nurses' experiences in psychiatric units with high risks of assault. Arch Psychiatr Nurs. 2005;19(4):169-75.
11. Ryan D, Maguire J. Aggression and violence - a problem in Irish Accident and Emergency departments? J Nurs Manag. 2006;14(2):106-15.
12. Clements PT, DeRanieri JT, Clark K, Manno MS, Kuhn DW. Workplace violence and corporate policy for health care settings. Nurs Econ. 2005;23(3):119-24, 07.
13. Catlette M. A descriptive study of the perceptions of workplace violence and safety strategies of nurses working in level I trauma centers. J Emerg Nurs. 2005;31(6):519-25.
14. Pich J, Hazelton M, Sundin D, Kable A. Patient-related violence against emergency department nurses. Nurs Health Sci. 2010;12(2):268-74.
15. Gacki-Smith J, Juarez AM, Boyett L, Homeyer C, Robinson L, MacLean SL. Violence against nurses working in US emergency departments. J Nurs Adm. 2009;39(7-8):340-9.
16. Workplace violence position statement [Available from: https://www.apna.org/i4a/pages/index.cfm?pageid=3786.
17. Association EN, editor Violence in the emergency department: Findings from ENA’s study of workplace violence against registered nurses. Annual Conference Course; 2008.
18. van der Zwan R, Davies L, Andrews D, Brooks A. Aggression and violence in the ED: issues associated with the implementation of restraint and seclusion. Health Promot J Austr. 2011;22(2):124-7.
19. Vilke GM, DeBard ML, Chan TC, Ho JD, Dawes DM, Hall C, et al. Excited Delirium Syndrome (ExDS): defining based on a review of the literature. J Emerg Med. 2012;43(5):897-905.
20. Gerberich SG, Church TR, McGovern PM, Hansen H, Nachreiner NM, Geisser MS, et al. Risk factors for work-related assaults on nurses. Epidemiology. 2005;16(5):704-9.
21. Kennedy MP. Violence in emergency departments: under-reported, unconstrained, and unconscionable. Med J Aust. 2005;183(7):362-5.
22. Ashton RA, Morris L, Smith I. A qualitative meta-synthesis of emergency department staff experiences of violence and aggression. Int Emerg Nurs. 2018;39:13-9.
23. Ferns T, Cork A, Rew M. Personal safety in the accident and emergency department. Br J Nurs. 2005;14(13):725-30.
24. Hahn S, Hantikainen V, Needham I, Kok G, Dassen T, Halfens RJ. Patient and visitor violence in the general hospital, occurrence, staff interventions and consequences: a cross-sectional survey. J Adv Nurs. 2012;68(12):2685-99.
25. Lau JB, Magarey J, Wiechula R. Violence in the emergency department: an ethnographic study (part II). Int Emerg Nurs. 2012;20(3):126-32.
26. Workplace Violence [Available from: https://www.nursingworld.org/practice-policy/advocacy/state/workplace-violence2/.
27. Li YF, Chao M, Shih CT. Nurses' intention to resign and avoidance of emergency department violence: A moderated mediation model. Int Emerg Nurs. 2018;39:55-61.
28. Nordstrom K, Allen MH. Managing the acutely agitated and psychotic patient. CNS Spectr. 2007;12(10 Suppl 17):5-11.
29. Violence Prevention and Management Training Framework for NSW Health Organisations [Available from: https://www1.health.nsw.gov.au/pds/Pages/doc.aspx?dn=PD2017_043.
30. Wassell JT. Workplace violence intervention effectiveness: A systematic literature review. Safe Sci. 2009;47(8):1049-55.
31. Varcoe C. Staring, tone of voice, anxiety, mumbling, and pacing in the ED were cues for violence toward nurses. Evid Based Nurs. 2008;11(1):29.
32. Morphet J, Griffiths D, Plummer V, Innes K, Fairhall R, Beattie J. At the crossroads of violence and aggression in the emergency department: perspectives of Australian emergency nurses. Aust Health Rev. 2014;38(2):194-201.
33. Luck L, Jackson D, Usher K. STAMP: components of observable behaviour that indicate potential for patient violence in emergency departments. J Adv Nurs. 2007;59(1):11-9.
34. Chapman R, Perry L, Styles I, Combs S. Predicting patient aggression against nurses in all hospital areas. Br J Nurs. 2009;18(8):476, 8-83.
35. Lasalvia A, Bonetto C, Cristofalo D, Tansella M, Ruggeri M. Predicting clinical and social outcome of patients attending 'real world' mental health services: a 6-year multi-wave follow-up study. Acta Psychiatr Scand Suppl. 2007(437):16-30.
36. Huber CG, Lambert M, Naber D, Schacht A, Hundemer HP, Wagner TT, et al. Validation of a Clinical Global Impression Scale for Aggression (CGI-A) in a sample of 558 psychiatric patients. Schizophr Res. 2008;100(1-3):342-8.
37. Douglas KS, Guy LS, Reeves KA, Weir J. HCR-20 violence risk assessment scheme: Overview and annotated bibliography. 2005. Implementation Science and Practice Advances Research Center Publications. 335.
38. Sachs GS, Gaulin BD, Gutierrez-Esteinou R, McQuade RD, Pikalov A, 3rd, Pultz JA, et al. Antimanic response to aripiprazole in bipolar I disorder patients is independent of the agitation level at baseline. J Clin Psychiatry. 2007;68(9):1377-83.
39. Currier GW, Citrome LL, Zimbroff DL, Oren D, Manos G, McQuade R, et al. Intramuscular aripiprazole in the control of agitation. J Psychiatr Pract. 2007;13(3):159-69.
40. Marder SR, West B, Lau GS, Pultz JA, Pikalov A, Marcus RN, et al. Aripiprazole effects in patients with acute schizophrenia experiencing higher or lower agitation: a post hoc analysis of 4 randomized, placebo-controlled clinical trials. J Clin Psychiatry. 2007;68(5):662-8.
41. Chaichan W. Evaluation of the use of the positive and negative syndrome scale-excited component as a criterion for administration of p.r.n. medication. J Psychiatr Pract. 2008;14(2):105-13.
42. Holloman GH, Jr., Zeller SL. Overview of Project BETA: Best practices in Evaluation and Treatment of Agitation. West J Emerg Med. 2012;13(1):1-2.
43. Richardson SK, Grainger PC, Ardagh MW, Morrison R. Violence and aggression in the emergency department is under-reported and under-appreciated. N Z Med J. 2018;131(1476):50-8.
44. Huckshorn KA. Re-designing state mental health policy to prevent the use of seclusion and restraint. Adm Policy Ment Health. 2006;33(4):482-91.
45. Knox DK, Holloman GH, Jr. Use and avoidance of seclusion and restraint: consensus statement of the american association for emergency psychiatry project Beta seclusion and restraint workgroup. West J Emerg Med. 2012;13(1):35-40.
46. Battaglia J. Pharmacological management of acute agitation. Drugs. 2005;65(9):1207-22.
47. MacDonald K, Wilson MP, Minassian A, Vilke GM, Perez R, Cobb P, et al. A retrospective analysis of intramuscular haloperidol and intramuscular olanzapine in the treatment of agitation in drug- and alcohol-using patients. Gen Hosp Psychiatry. 2010;32(4):443-5.
48. Vilke GM, Wilson MP, Lovecchio F. Agitation: what every emergency physician should know. Emerg Med Rep. 2009;30(19):233-43.
49. Pourshaikhian M, Abolghasem Gorji H, Aryankhesal A, Khorasani-Zavareh D, Barati A. A Systematic Literature Review: Workplace Violence Against Emergency Medical Services Personnel. Arch Trauma Res. 2016;5(1):e28734.
50. Petit JR. Management of the acutely violent patient. Psychiatr Clin North Am. 2005;28(3):701-11, 710.
51. Marco CA, Vaughan J. Emergency management of agitation in schizophrenia. Am J Emerg Med. 2005;23(6):767-76.
52. Peluso MJ, Lewis SW, Barnes TR, Jones PB. Extrapyramidal motor side-effects of first- and second-generation antipsychotic drugs. Br J Psychiatry. 2012;200(5):387-92.
53. Jibson MD. First-generation antipsychotic medications: Pharmacology, administration, and comparative side effects. UptoDate Waltham, MA(Accessed June 17, 2014). 2014.
54. Gao K, Kemp DE, Ganocy SJ, Gajwani P, Xia G, Calabrese JR. Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review. J Clin Psychopharmacol. 2008;28(2):203-9.
55. Leucht S, Cipriani A, Spineli L, Mavridis D, Örey D, Richter F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951-62.
56. Baldacara L, Sanches M, Cordeiro DC, Jackoswski AP. Rapid tranquilization for agitated patients in emergency psychiatric rooms: a randomized trial of olanzapine, ziprasidone, haloperidol plus promethazine, haloperidol plus midazolam and haloperidol alone. Braz J Psychiatry. 2011;33(1):30-9.
57. Mantovani C, Migon MN, Alheira FV, Del-Ben CM. Management of the violent or agitated patient. Braz J Psychiatry. 2010;32 Suppl 2:S96-103.
58. Wilson MP, MacDonald K, Vilke GM, Feifel D. A comparison of the safety of olanzapine and haloperidol in combination with benzodiazepines in emergency department patients with acute agitation. J Emerg Med. 2012;43(5):790-7.
59. Huf G, Coutinho ES, Adams CE. Haloperidol plus promethazine for agitated patients--a systematic review. Braz J Psychiatry. 2009;31(3):265-70.
60. Food U, Administration D. Information for healthcare professionals: haloperidol (marketed as Haldol, Haldol Decanoate and Haldol Lactate). US Food and Drug Administration Rockville, MD. 2007.
61. Meyer-Massetti C, Cheng CM, Sharpe BA, Meier CR, Guglielmo BJ. The FDA extended warning for intravenous haloperidol and torsades de pointes: how should institutions respond? J Hosp Med. 2010;5(4):E8-16.
62. Zemrak WR, Kenna GA. Association of antipsychotic and antidepressant drugs with Q-T interval prolongation. Am J Health Syst Pharm. 2008;65(11):1029-38.
63. Li M, Liz GR. Drug-Induced QT Prolongation And Torsades de Pointes. P T. 2017;42(7): 473-7.
64. Alvarez PA, Pahissa J. QT alterations in psychopharmacology: proven candidates and suspects. Curr Drug Saf. 2010;5(1):97-104.
65. Muzyk AJ, Rayfield A, Revollo JY, Heinz H, Gagliardi JP. Examination of baseline risk factors for QTc interval prolongation in patients prescribed intravenous haloperidol. Drug Saf. 2012;35(7):547-53.
66. Lopez-Munoz F, Alamo C, Cuenca E, Shen WW, Clervoy P, Rubio G. History of the discovery and clinical introduction of chlorpromazine. Ann Clin Psychiatry. 2005;17(3):113-35.
67. Turner T. Chlorpromazine: unlocking psychosis. BMJ. 2007;334 Suppl 1:s7.
68. Excellence NIfC. The short-term management of disturbed/violent behaviour in in-patient psychiatric settings and emergency departments. London: NICE. 2005.
69. Ahmed U, Jones H, Adams CE. Chlorpromazine for psychosis induced aggression or agitation. Cochrane Database Syst Rev. 2010(4):Cd007445.
70. Haro JM, Salvador-Carulla L. The SOHO (Schizophrenia Outpatient Health Outcome) study: implications for the treatment of schizophrenia. CNS drugs. 2006;20(4):293-301.
71. Ucok A, Gaebel W. Side effects of atypical antipsychotics: a brief overview. World psychiatry. 2008;7(1):58-62.
72. Kroken RA, Johnsen E, Ruud T, Wentzel-Larsen T, Jorgensen HA. Treatment of schizophrenia with antipsychotics in Norwegian emergency wards, a cross-sectional national study. BMC psychiatry. 2009;9:24.
73. Marder SR. A review of agitation in mental illness: treatment guidelines and current therapies. The J Clin Psychiatry. 2006;67 Suppl 10:13-21.
74. Zeller SL, Rhoades RW. Systematic reviews of assessment measures and pharmacologic treatments for agitation. Clin Ther. 2010;32(3):403-25.
75. Ray WA, Chung CP, Murray KT, Hall K, Stein CM. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med. 2009;360(3):225-35.
76. Oliveira IR, Nunes PM, Coutinho DM, Sena EP. Review of the efficacy of placebo in comparative clinical trials between typical and atypical antipsychotics. Braz J Psychiatry. 2009;31(1):52-6.
77. Brook S, Walden J, Benattia I, Siu CO, Romano SJ. Ziprasidone and haloperidol in the treatment of acute exacerbation of schizophrenia and schizoaffective disorder: comparison of intramuscular and oral formulations in a 6-week, randomized, blinded-assessment study. Psychopharmacology. 2005;178(4):514-23.
78. Satterthwaite TD, Wolf DH, Rosenheck RA, Gur RE, Caroff SN. A meta-analysis of the risk of acute extrapyramidal symptoms with intramuscular antipsychotics for the treatment of agitation. J Clin Psychiatry. 2008;69(12):1869-79.
79. Andrezina R, Josiassen RC, Marcus RN, Oren DA, Manos G, Stock E, et al. Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol. Psychopharmacology. 2006;188(3):281-92.
80. Raveendran NS, Tharyan P, Alexander J, Adams CE. Rapid tranquillisation in psychiatric emergency settings in India: pragmatic randomised controlled trial of intramuscular olanzapine versus intramuscular haloperidol plus promethazine. BMJ. 2007;335(7625):865.
81. Newcomer JW. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin Psychiatry. 2007;68 Suppl 1:20-7.
82. Gaebel W, Weinmann S, Sartorius N, Rutz W, McIntyre JS. Schizophrenia practice guidelines: international survey and comparison. Br J Psychiatry. 2005;187:248-55.
83. Tandon R, Belmaker RH, Gattaz WF, Lopez-Ibor JJ, Jr., Okasha A, Singh B, et al. World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. Schizophr Res. 2008;100(1-3):20-38.
84. Centorrino F, Meyers AL, Ahl J, Cincotta SL, Zun L, Gulliver AH, et al. An observational study of the effectiveness and safety of intramuscular olanzapine in the treatment of acute agitation in patients with bipolar mania or schizophrenia/schizoaffective disorder. Hum Psychopharmacol. 2007;22(7):455-62.
85. Damsa C, Adam E, Lazignac C, De Gregorio F, Mihai A, Lejeune J, et al. Intramuscular olanzapine in patients with schizophrenia: an observational study in an emergency room. Bull Soc Sci Med Grand Duche Luxemb. 2008(2):209-16.
86. Jangro WC, Preval H, Southard R, Klotz SG, Francis A. Conventional intramuscular sedatives versus ziprasidone for severe agitation in adolescents: case-control study. Child Adolesc Psychiatry Ment Health. 2009;3(1):9.
87. Kohen I, Preval H, Southard R, Francis A. Naturalistic study of intramuscular ziprasidone versus conventional agents in agitated elderly patients: retrospective findings from a psychiatric emergency service. Am J Geriatr Pharmacother. 2005;3(4):240-5.
88. Martel M, Sterzinger A, Miner J, Clinton J, Biros M. Management of acute undifferentiated agitation in the emergency department: a randomized double-blind trial of droperidol, ziprasidone, and midazolam. Acad Emerg Med. 2005;12(12):1167-72.
89. Preval H, Klotz SG, Southard R, Francis A. Rapid-acting IM ziprasidone in a psychiatric emergency service: a naturalistic study. Gen Hosp Psychiatry. 2005;27(2):140-4.
90. San L, Arranz B, Querejeta I, Barrio S, De la Gandara J, Perez V. A naturalistic multicenter study of intramuscular olanzapine in the treatment of acutely agitated manic or schizophrenic patients. Eur Psychiatry. 2006;21(8):539-43.
91. Veser FH, Veser BD, McMullan JT, Zealberg J, Currier GW. Risperidone versus haloperidol, in combination with lorazepam, in the treatment of acute agitation and psychosis: a pilot, randomized, double-blind, placebo-controlled trial. J Psychiatr Pract. 2006;12(2):103-8.
92. Zimbroff DL, Marcus RN, Manos G, Stock E, McQuade RD, Auby P, et al. Management of acute agitation in patients with bipolar disorder: efficacy and safety of intramuscular aripiprazole. J Clin Psychopharmacol. 2007;27(2):171-6.
93. Tran-Johnson TK, Sack DA, Marcus RN, Auby P, McQuade RD, Oren DA. Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2007;68(1):111-9.
94. Scherk H, Pajonk FG, Leucht S. Second-generation antipsychotic agents in the treatment of acute mania: a systematic review and meta-analysis of randomized controlled trials. Arch Gen Psychiatry. 2007;64(4):442-55.
95. Smith LA, Cornelius V, Warnock A, Tacchi MJ, Taylor D. Pharmacological interventions for acute bipolar mania: a systematic review of randomized placebo-controlled trials. Bipolar Disord. 2007;9(6):551-60.
96. Hsu WY, Huang SS, Lee BS, Chiu NY. Comparison of intramuscular olanzapine, orally disintegrating olanzapine tablets, oral risperidone solution, and intramuscular haloperidol in the management of acute agitation in an acute care psychiatric ward in Taiwan. J Clin Psychopharmacol. 2010;30(3):230-4.
97. Hatta K, Kawabata T, Yoshida K, Hamakawa H, Wakejima T, Furuta K, et al. Olanzapine orally disintegrating tablet vs. risperidone oral solution in the treatment of acutely agitated psychotic patients. Gen Hosp Psychiatry. 2008;30(4):367-71.
98. Lim HK, Kim JJ, Pae CU, Lee CU, Lee C, Paik IH. Comparison of risperidone orodispersible tablet and intramuscular haloperidol in the treatment of acute psychotic agitation: a randomized open, prospective study. Neuropsychobiology. 2010;62(2):81-6.
99. Villari V, Rocca P, Fonzo V, Montemagni C, Pandullo P, Bogetto F. Oral risperidone, olanzapine and quetiapine versus haloperidol in psychotic agitation. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(2):405-13.
100. Hovens JE, Dries PJ, Melman CT, Wapenaar RJ, Loonen AJ. Oral risperidone with lorazepam versus oral zuclopenthixol with lorazepam in the treatment of acute psychosis in emergency psychiatry: a prospective, comparative, open-label study. J Psychopharmacol. 2005;19(1):51-7.
101. Pascual JC, Perez V, Martin JL, Safont G, Puigdemont D, Alvarez E. Olanzapine orally-disintegrating tablet in severe psychotic agitation: a naturalistic study. Actas Esp Psiquiatr. 2007;35(1):47-51.
102. Citrome L. Comparison of intramuscular ziprasidone, olanzapine, or aripiprazole for agitation: a quantitative review of efficacy and safety. J Clin Psychiatry. 2007;68(12):1876-85.
103. Mohr P, Pecenak J, Svestka J, Swingler D, Treuer T. Treatment of acute agitation in psychotic disorders. Neuro Endocrinol Lett. 2005;26(4):327-35.
104. Castle DJ, Udristoiu T, Kim CY, Sarosi A, Pidrman V, Omar AN, et al. Intramuscular olanzapine versus short-acting typical intramuscular antipsychotics: comparison of real-life effectiveness in the treatment of agitation. World J Biol Psychiatry. 2009;10(1):43-53.
105. Green AI, Lieberman JA, Hamer RM, Glick ID, Gur RE, Kahn RS, et al. Olanzapine and haloperidol in first episode psychosis: two-year data. Schizophr Res. 2006;86(1-3):234-43.
106. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373(9657):31-41.
107. Belgamwar RB, Fenton M. Olanzapine IM or velotab for acutely disturbed/agitated people with suspected serious mental illnesses. Cochrane Database Syst Rev. 2005(2):Cd003729.
108. Kinon BJ, Stauffer VL, Kollack-Walker S, Chen L, Sniadecki J. Olanzapine versus aripiprazole for the treatment of agitation in acutely ill patients with schizophrenia. J Clin Psychopharmacol. 2008;28(6):601-7.
109. Marder SR, Sorsaburu S, Dunayevich E, Karagianis JL, Dawe IC, Falk DM, et al. Case reports of postmarketing adverse event experiences with olanzapine intramuscular treatment in patients with agitation. J Clin Psychiatry. 2010;71(4):433-41.
110. Lonergan E, Britton AM, Luxenberg J, Wyller T. Antipsychotics for delirium. Cochrane Database Syst Rev. 2007(2):Cd005594.
111. Lilly E. Zyprexa (olanzapine) package insert. Indianapolis, IN. 2005.
112. Zacher JL, Roche-Desilets J. Hypotension secondary to the combination of intramuscular olanzapine and intramuscular lorazepam. J Clin Psychiatry. 2005;66(12):1614-5.
113. Smith MA, McCoy R, Hamer-Maansson J, Brecher M. Rapid dose escalation with quetiapine: a pilot study. J Clin Psychopharmacol. 2005;25(4):331-5.
114. Currier GW, Trenton AJ, Walsh PG, van Wijngaarden E. A pilot, open-label safety study of quetiapine for treatment of moderate psychotic agitation in the emergency setting. J Psychiatr Pract. 2006;12(4):223-8.
115. Warrington L, Lombardo I, Loebel A, Ice K. Ziprasidone for the treatment of acute manic or mixed episodes associated with bipolar disorder. CNS drugs. 2007;21(10):835-49.
116. Zimbroff DL, Allen MH, Battaglia J, Citrome L, Fishkind A, Francis A, et al. Best clinical practice with ziprasidone IM: update after 2 years of experience. CNS Spectr. 2005;10(9):1-15.
117. Barzman DH, DelBello MP, Forrester JJ, Keck PE, Jr., Strakowski SM. A retrospective chart review of intramuscular ziprasidone for agitation in children and adolescents on psychiatric units: prospective studies are needed. J Child Adolesc Psychopharmacol. 2007;17(4):503-9.
118. De Filippis S, Cuomo I, Lionetto L, Janiri D, Simmaco M, Caloro M, et al. Intramuscular aripiprazole in the acute management of psychomotor agitation. Pharmacotherapy. 2013;33(6):603-14.
119. Mauri MC, Steinhilber CP, Marino R, Invernizzi E, Fiorentini A, Cerveri G, et al. Clinical outcome and olanzapine plasma levels in acute schizophrenia. Eur Psychiatry. 2005;20(1):55-60.
120. Nozawa M, Ohnuma T, Matsubara Y, Sakai Y, Hatano T, Hanzawa R, et al. The relationship between the response of clinical symptoms and plasma olanzapine concentration, based on pharmacogenetics: Juntendo University Schizophrenia Projects (JUSP). Ther Drug Monit. 2008;30(1):35-40.
121. McIntyre J, Robertson S, Norris E, Appleton R, Whitehouse WP, Phillips B, et al. Safety and efficacy of buccal midazolam versus rectal diazepam for emergency treatment of seizures in children: a randomised controlled trial. Lancet. 2005;366(9481):205-10.
122. Mehta V, Singhi P, Singhi S. Intravenous sodium valproate versus diazepam infusion for the control of refractory status epilepticus in children: a randomized controlled trial. J Child Neurol. 2007;22(10):1191-7.
123. Pellock JM, Shinnar S. Respiratory adverse events associated with diazepam rectal gel. Neurology. 2005;64(10):1768-70.
124. McMullan J, Sasson C, Pancioli A, Silbergleit R. Midazolam versus diazepam for the treatment of status epilepticus in children and young adults: a meta-analysis. Acad Emerg Med. 2010;17(6):575-82.
125. Vincent J-L, Shehabi Y, Walsh TS, Pandharipande PP, Ball JA, Spronk P, et al. Comfort and patient-centred care without excessive sedation: the eCASH concept. Intensive Care Med. 2016;42(6):962-71.
126. Rund DA, Ewing JD, Mitzel K, Votolato N. The use of intramuscular benzodiazepines and antipsychotic agents in the treatment of acute agitation or violence in the emergency department. J Emerg Med. 2006;31(3):317-24.
127. Licata SC, Platt DM, Cook JM, Van Linn ML, Rowlett JK. Contribution of alpha1 subunit-containing gamma-aminobutyric acidA (GABAA) receptors to motor-impairing effects of benzodiazepines in squirrel monkeys. Psychopharmacology. 2009;203(3):539-46.
128. Papineni A, Lourenco-Matharu L, Ashley PF. Safety of oral midazolam sedation use in paediatric dentistry: a review. Int J Paediatr Dent. 2014;24(1):2-13.
129. MacDonald K, Wilson M, Minassian A, Vilke GM, Becker O, Tallian K, et al. A naturalistic study of intramuscular haloperidol versus intramuscular olanzapine for the management of acute agitation. J Clin Psychopharmacol. 2012;32(3):317-22.
130. Gillies D, Beck A, McCloud A, Rathbone J, Gillies D. Benzodiazepines alone or in combination with antipsychotic drugs for acute psychosis. Cochrane Database Syst Rev. 2005(4):Cd003079.
131. Pacciardi B, Mauri M, Cargioli C, Belli S, Cotugno B, Di Paolo L, et al. Issues in the management of acute agitation: how much current guidelines consider safety? Front Psychiatry. 2013;4:26.
132. Arcangeli A, Antonelli M, Mignani V, Sandroni C. Sedation in PACU: the role of benzodiazepines. Curr Drug Targets. 2005;6(7):745-8.
133. Boomsma MM, Mengels O, van Olden RW. Risks associated with parenteral treatment of acute agitation. Tijdschr Psychiatr. 2006;48(2):135-9.
134. Wilson MP, MacDonald K, Vilke GM, Feifel D. Potential complications of combining intramuscular olanzapine with benzodiazepines in emergency department patients. J Emerg Med. 2012;43(5):889-96.
135. Cunha M, André S, Bica I, Ribeiro O, Dias A, Andrade A. Chemical and physical restraint of patients. Procedia Soc Behav Sci. 2016;217:389-99.
136. Leahy-Warren P, Varghese V, Day MR, Curtin M. Physical restraint: perceptions of nurse managers, registered nurses and healthcare assistants. Int Nurs Rev. 2018;65(3):327-35.
137. Gildberg FA, Fristed P, Makransky G, Moeller EH, Nielsen LD, Bradley SK. As time goes by: reasons and characteristics of prolonged episodes of mechanical restraint in forensic psychiatry. J Forensic Nurs. 2015;11(1):41-50.
138. Hui A, Middleton H, Völlm B. Coercive measures in forensic settings: Findings from the literature. Int J Forensic Ment Health. 2013;12(1):53-67.
139. Cannon M, Sprivulis P, McCarthy J. Restraint practices in Australasian emergency departments. The Aust N Z J Psychiatry. 2001;35(4):464-7.
140. Martin B, Mathisen L. Use of physical restraints in adult critical care: a bicultural study. Am J Crit Care. 2005;14(2):133-42.
141. Mason J, Colwell CB, Grock A. Agitation Crisis Control. Ann Emerg Med. 2018;72(4):371-3.
142. Coburn VA, Mycyk MB. Physical and chemical restraints. Emerg Med Clin North Am. 2009;27(4):655-67, ix.
143. Wilson EB. Physical restraint of elderly patients in critical care: historical perspectives and new directions. Crit Care Nurs Clin North Am. 1996;8(1):61-70.
144. Physicians ACoE. Use of patient restraints. Policy statement. Ann Emerg Med. 2014;64(5):574.
145. James A, Madeley R, Dove A. Violence and aggression in the emergency department. Emerg Med J. 2006;23(6):431-4.
146. Pich J, Hazelton M, Sundin D, Kable A. Patient-related violence at triage: A qualitative descriptive study. Int Emerg Nurs. 2011;19(1):12-9.
147. Baskin-Sommers A, Sommers I. Methamphetamine Use and Violence Among Young Adults. J Crim Justice 2006;34(6):661-74.
148. Holleran RS. Preventing staff injuries from violence. J Emerg Nurs. 2006;32(6):523-4.
149. Gates D, Ross C, McQueen L. Violence: Recognition, management and prevention. J Emerg Med. 2005;31(3):331-7.
150. Landau SF, Bendalak Y. Personnel exposure to violence in hospital emergency wards: a routine activity approach. Aggress Behav. 2008;34(1):88-103.
151. Gilchrist H, Jones SC, Barrie L. Experiences of emergency department staff: Alcohol-related and other violence and aggression. Australas Emerg Nurs J. 2011;14(1):9-16.
152. Gillespie GL, Gates DM, Miller M, Howard PK. Emergency department workers' perceptions of security officers' effectiveness during violent events. Work. 2012;42(1):21-7.
153. Wand TC, Coulson K. Zero tolerance: a policy in conflict with current opinion on aggression and violence management in health care. Australas Emerg Nurs J. 2006;9(4):163-70.
154. Mackay I, Paterson B, Cassells C. Constant or special observations of inpatients presenting a risk of aggression or violence: nurses' perceptions of the rules of engagement. J Psychiatr Ment Health Nurs. 2005;12(4):464-71.
155. Ramacciati N, Ceccagnoli A, Addey B, Rasero L. Violence towards Emergency Nurses. The Italian National Survey 2016: A qualitative study. Int J Nurs Stud. 2018;81:21-9.
156. Allen MH, Currier GW, Carpenter D, Ross RW, Docherty JP. The expert consensus guideline series. Treatment of behavioral emergencies 2005. J Psychiatr Pract. 2005;11 Suppl 1:5-108; quiz 10-2.
157. Currier GW. The controversy over "chemical restraint" in acute care psychiatry. J Psychiatr Pract. 2003;9(1):59-70.
158. Hopper AB, Vilke GM, Castillo EM, Campillo A, Davie T, Wilson MP. Ketamine use for acute agitation in the emergency department. J Emerg Med. 2015;48(6):712-9.
159. Alexopoulos GS, Streim J, Carpenter D, Docherty JP. Using antipsychotic agents in older patients. J Clin Psychiatry. 2004;65 Suppl 2:5-99; discussion 100-2; quiz 3-4.
160. Gerson R, Malas N, Mroczkowski MM. Crisis in the Emergency Department: The Evaluation and Management of Acute Agitation in Children and Adolescents. Child Adolesc Psychiatr Clin N Am. 2018;27(3):367-86.
161. Vieta E, Garriga M, Cardete L, Bernardo M, Lombrana M, Blanch J, et al. Protocol for the management of psychiatric patients with psychomotor agitation. BMC psychiatry. 2017;17(1):328.
162. Larue C, Dumais A, Ahern E, Bernheim E, Mailhot MP. Factors influencing decisions on seclusion and restraint. J Psychiatr Ment Health Nurs. 2009;16(5):440-6.
163. Farina-Lopez E, Estevez-Guerra GJ, Polo-Luque ML, Hanzelikova Pogranyiva A, Penelo E. Physical Restraint Use With Elderly Patients: Perceptions of Nurses and Nursing Assistants in Spanish Acute Care Hospitals. Nurs Res. 2018;67(1):55-9.
164. Laiho T, Kattainen E, Astedt-Kurki P, Putkonen H, Lindberg N, Kylma J. Clinical decision making involved in secluding and restraining an adult psychiatric patient: an integrative literature review. J Psychiatr Ment Health Nurs. 2013;20(9):830-9.
165. Kallert TW. Involuntary psychiatric hospitalization: current status and future prospects. Srp Arh Celok Lek. 2011;139 Suppl 1:14-20.
166. Hodge AN, Marshall AP. Violence and aggression in the emergency department: a critical care perspective. Aust Crit Care. 2007;20(2):61-7.
167. Perkins E, Prosser H, Riley D, Whittington R. Physical restraint in a therapeutic setting; a necessary evil? Int J Law Psychiatry. 2012;35(1):43-9.
168. De Hert M, Einfinger G, Scherpenberg E, Wampers M, Peuskens J. The prevention of deep venous thrombosis in physically restrained patients with schizophrenia. Int J Clin Pract. 2010;64(8):1109-15.
169. Maly R, Masopust J, Hosak L, Konupcikova K. Assessment of risk of venous thromboembolism and its possible prevention in psychiatric patients. Psychiatry Clin Neurosci. 2008;62(1):3-8.
170. Steinert T, Lepping P, Bernhardsgrutter R, Conca A, Hatling T, Janssen W, et al. Incidence of seclusion and restraint in psychiatric hospitals: a literature review and survey of international trends. Soc Psychiatry Psychiatr Epidemiol. 2010;45(9):889-97.
171. Cecchi R, Lazzaro A, Catanese M, Mandarelli G, Ferracuti S. Fatal thromboembolism following physical restraint in a patient with schizophrenia. Int J Legal Med. 2012;126(3):477-82.
172. Dickson BC, Pollanen MS. Fatal thromboembolic disease: a risk in physically restrained psychiatric patients. J Forensic Leg Med. 2009;16(5):284-6.
173. Ishida T, Katagiri T, Uchida H, Takeuchi H, Sakurai H, Watanabe K, et al. Incidence of deep vein thrombosis in restrained psychiatric patients. Psychosomatics. 2014;55(1):69-75.
174. Karger B, Fracasso T, Pfeiffer H. Fatalities related to medical restraint devices-asphyxia is a common finding. Forensic Sci Int. 2008;178(2-3):178-84.
175. Laursen SB, Jensen TN, Bolwig T, Olsen NV. Deep venous thrombosis and pulmonary embolism following physical restraint. Acta Psychiatr Scand. 2005;111(4):324-7; discussion 7.
176. Rakhmatullina M, Taub A, Jacob T. Morbidity and mortality associated with the utilization of restraints : a review of literature. Psychiatr Q. 2013;84(4):499-512.
177. Cowman S, Bjorkdahl A, Clarke E, Gethin G, Maguire J. A descriptive survey study of violence management and priorities among psychiatric staff in mental health services, across seventeen european countries. BMC Health Serv Res. 2017;17(1):59.
178. Nelstrop L, Chandler-Oatts J, Bingley W, Bleetman T, Corr F, Cronin-Davis J, et al. A systematic review of the safety and effectiveness of restraint and seclusion as interventions for the short-term management of violence in adult psychiatric inpatient settings and emergency departments. Worldviews Evid Based Nurs. 2006;3(1):8-18.
179. Paterson B, McIntosh I, Wilkinson D, McComish S, Smith I. Corrupted cultures in mental health inpatient settings. Is restraint reduction the answer? J Psychiatr Ment Health Nurs. 2013;20(3):228-35.
180. An FR, Sha S, Zhang QE, Ungvari GS, Ng CH, Chiu HF, et al. Physical restraint for psychiatric patients and its associations with clinical characteristics and the National Mental Health Law in China. Psychiatry Res. 2016;241:154-8.
181. Steinert T, Lepping P. Legal provisions and practice in the management of violent patients. a case vignette study in 16 European countries. Eur Psychiatry. 2009;24(2):135-41.
182. Azeem MW, Aujla A, Rammerth M, Binsfeld G, Jones RB. Effectiveness of six core strategies based on trauma informed care in reducing seclusions and restraints at a child and adolescent psychiatric hospital. J Child Adolesc Psychiatr Nurs. 2011;24(1):11-5.
183. Hellerstein DJ, Staub AB, Lequesne E. Decreasing the use of restraint and seclusion among psychiatric inpatients. J Psychiatr Pract. 2007;13(5):308-17.
184. Martin A, Krieg H, Esposito F, Stubbe D, Cardona L. Reduction of restraint and seclusion through collaborative problem solving: a five-year prospective inpatient study. Psychiatr Serv. 2008;59(12):1406-12.
185. Currier GW, Walsh P, Lawrence D. Physical restraints in the emergency department and attendance at subsequent outpatient psychiatric treatment. J Psychiatr Pract. 2011;17(6):387-93.
186. Demir A. Nurses' use of physical restraints in four Turkish hospitals. J Nurs Scholarsh. 2007;39(1):38-45.
187. Downes MA, Healy P, Page CB, Bryant JL, Isbister GK. Structured team approach to the agitated patient in the emergency department. Emerg Med Australas. 2009;21(3):196-202.
188. Dumais A, Larue C, Drapeau A, Menard G, Giguere Allard M. Prevalence and correlates of seclusion with or without restraint in a Canadian psychiatric hospital: a 2-year retrospective audit. J Psychiatr Ment Health Nurs. 2011;18(5):394-402.
189. Lane C, Harrington A. The factors that influence nurses' use of physical restraint: A thematic literature review. Int J Nurs Prac. 2011;17(2):195-204.
190. Gelkopf M, Roffe Z, Behrbalk P, Melamed Y, Werbloff N, Bleich A. Attitudes, opinions, behaviors, and emotions of the nursing staff toward patient restraint. Issues Ment Health Nurs. 2009;30(12):758-63.
191. Gerace A, Pamungkas DR, Oster C, Thomson D, Muir-Cochrane E. The use of restraint in four general hospital emergency departments in Australia. Australas Psychiatry. 2014;22(4):366-9.
192. Raboch J, Kalisova L, Nawka A, Kitzlerova E, Onchev G, Karastergiou A, et al. Use of coercive measures during involuntary hospitalization: findings from ten European countries. Psychiatr Serv. 2010;61(10):1012-7.
193. Knutzen M, Sandvik L, Hauff E, Opjordsmoen S, Friis S. Association between patients' gender, age and immigrant background and use of restraint--a 2-year retrospective study at a department of emergency psychiatry. Nord J Psychiatry. 2007;61(3):201-6.
194. Knutzen M, Bjorkly S, Eidhammer G, Lorentzen S, Helen Mjosund N, Opjordsmoen S, et al. Mechanical and pharmacological restraints in acute psychiatric wards--why and how are they used? Psychiatry Res. 2013;209(1):91-7.
195. Knutzen M, Bjorkly S, Eidhammer G, Lorentzen S, Mjosund NH, Opjordsmoen S, et al. Characteristics of patients frequently subjected to pharmacological and mechanical restraint--a register study in three Norwegian acute psychiatric wards. Psychiatry Res. 2014;215(1):127-33.
196. Kontio R, Joffe G, Putkonen H, Kuosmanen L, Hane K, Holi M, et al. Seclusion and restraint in psychiatry: patients' experiences and practical suggestions on how to improve practices and use alternatives. Perspect Psychiatr Care. 2012;48(1):16-24.
197. Mayers P, Keet N, Winkler G, Flisher AJ. Mental health service users' perceptions and experiences of sedation, seclusion and restraint. Int J Soc Psychiatry. 2010;56(1):60-73.
198. McCurdy JM, Haliburton JR, Yadav HC, Yoder AM, Norton LR, Froehlich JA, et al. Case study: design may influence use of seclusion and restraint. Herd. 2015;8(3):116-21.
199. Migon MN, Coutinho ES, Huf G, Adams CE, Cunha GM, Allen MH. Factors associated with the use of physical restraints for agitated patients in psychiatric emergency rooms. Gen Hosp Psychiatry. 2008;30(3):263-8.
200. Khatib A, Ibrahim M, Roe D. Re-building Trust after Physical Restraint During Involuntary Psychiatric Hospitalization. Arch Psychiatr Nurs. 2018;32(3):457-61.
2. Zampieron A, Galeazzo M, Turra S, Buja A. Perceived aggression towards nurses: study in two Italian health institutions. J Clin Nurs. 2010;19(15-16):2329-41.
3. Alameddine M, Kazzi A, El-Jardali F, Dimassi H, Maalouf S. Occupational violence at Lebanese emergency departments: prevalence, characteristics and associated factors. J Occup Health. 2011;53(6):455-64.
4. Esmaeilpour M, Salsali M, Ahmadi F. Workplace violence against Iranian nurses working in emergency departments. Int Nurs Rev. 2011;58(1):130-7.
5. Rafati Rahimzadeh M, Zabihi A, Hosseini S. Verbal and physical violence on nurses in hospitals of Babol University of Medical Sciences. Hayat. 2011;17(2):5-11.
6. Hilliar K. Police-recorded assaults on hospital premises in New South Wales: 1996-2006. Crim Just Bull. 2008;16:1-12
7. Lau JB, Magarey J, McCutcheon H. Violence in the emergency department: a literature review. Australas Emerg Nurs J. 2004;7(2):27-37.
8. Nurses and Violence in the Workplace [Available from: https://www.ausmed.com/articles/nurses-and-violence-in-the-workplace/.
9. Ferns T. Violence in the accident and emergency department--an international perspective. Accid Emerg Nurs. 2005;13(3):180-5.
10. Kindy D, Petersen S, Parkhurst D. Perilous work: nurses' experiences in psychiatric units with high risks of assault. Arch Psychiatr Nurs. 2005;19(4):169-75.
11. Ryan D, Maguire J. Aggression and violence - a problem in Irish Accident and Emergency departments? J Nurs Manag. 2006;14(2):106-15.
12. Clements PT, DeRanieri JT, Clark K, Manno MS, Kuhn DW. Workplace violence and corporate policy for health care settings. Nurs Econ. 2005;23(3):119-24, 07.
13. Catlette M. A descriptive study of the perceptions of workplace violence and safety strategies of nurses working in level I trauma centers. J Emerg Nurs. 2005;31(6):519-25.
14. Pich J, Hazelton M, Sundin D, Kable A. Patient-related violence against emergency department nurses. Nurs Health Sci. 2010;12(2):268-74.
15. Gacki-Smith J, Juarez AM, Boyett L, Homeyer C, Robinson L, MacLean SL. Violence against nurses working in US emergency departments. J Nurs Adm. 2009;39(7-8):340-9.
16. Workplace violence position statement [Available from: https://www.apna.org/i4a/pages/index.cfm?pageid=3786.
17. Association EN, editor Violence in the emergency department: Findings from ENA’s study of workplace violence against registered nurses. Annual Conference Course; 2008.
18. van der Zwan R, Davies L, Andrews D, Brooks A. Aggression and violence in the ED: issues associated with the implementation of restraint and seclusion. Health Promot J Austr. 2011;22(2):124-7.
19. Vilke GM, DeBard ML, Chan TC, Ho JD, Dawes DM, Hall C, et al. Excited Delirium Syndrome (ExDS): defining based on a review of the literature. J Emerg Med. 2012;43(5):897-905.
20. Gerberich SG, Church TR, McGovern PM, Hansen H, Nachreiner NM, Geisser MS, et al. Risk factors for work-related assaults on nurses. Epidemiology. 2005;16(5):704-9.
21. Kennedy MP. Violence in emergency departments: under-reported, unconstrained, and unconscionable. Med J Aust. 2005;183(7):362-5.
22. Ashton RA, Morris L, Smith I. A qualitative meta-synthesis of emergency department staff experiences of violence and aggression. Int Emerg Nurs. 2018;39:13-9.
23. Ferns T, Cork A, Rew M. Personal safety in the accident and emergency department. Br J Nurs. 2005;14(13):725-30.
24. Hahn S, Hantikainen V, Needham I, Kok G, Dassen T, Halfens RJ. Patient and visitor violence in the general hospital, occurrence, staff interventions and consequences: a cross-sectional survey. J Adv Nurs. 2012;68(12):2685-99.
25. Lau JB, Magarey J, Wiechula R. Violence in the emergency department: an ethnographic study (part II). Int Emerg Nurs. 2012;20(3):126-32.
26. Workplace Violence [Available from: https://www.nursingworld.org/practice-policy/advocacy/state/workplace-violence2/.
27. Li YF, Chao M, Shih CT. Nurses' intention to resign and avoidance of emergency department violence: A moderated mediation model. Int Emerg Nurs. 2018;39:55-61.
28. Nordstrom K, Allen MH. Managing the acutely agitated and psychotic patient. CNS Spectr. 2007;12(10 Suppl 17):5-11.
29. Violence Prevention and Management Training Framework for NSW Health Organisations [Available from: https://www1.health.nsw.gov.au/pds/Pages/doc.aspx?dn=PD2017_043.
30. Wassell JT. Workplace violence intervention effectiveness: A systematic literature review. Safe Sci. 2009;47(8):1049-55.
31. Varcoe C. Staring, tone of voice, anxiety, mumbling, and pacing in the ED were cues for violence toward nurses. Evid Based Nurs. 2008;11(1):29.
32. Morphet J, Griffiths D, Plummer V, Innes K, Fairhall R, Beattie J. At the crossroads of violence and aggression in the emergency department: perspectives of Australian emergency nurses. Aust Health Rev. 2014;38(2):194-201.
33. Luck L, Jackson D, Usher K. STAMP: components of observable behaviour that indicate potential for patient violence in emergency departments. J Adv Nurs. 2007;59(1):11-9.
34. Chapman R, Perry L, Styles I, Combs S. Predicting patient aggression against nurses in all hospital areas. Br J Nurs. 2009;18(8):476, 8-83.
35. Lasalvia A, Bonetto C, Cristofalo D, Tansella M, Ruggeri M. Predicting clinical and social outcome of patients attending 'real world' mental health services: a 6-year multi-wave follow-up study. Acta Psychiatr Scand Suppl. 2007(437):16-30.
36. Huber CG, Lambert M, Naber D, Schacht A, Hundemer HP, Wagner TT, et al. Validation of a Clinical Global Impression Scale for Aggression (CGI-A) in a sample of 558 psychiatric patients. Schizophr Res. 2008;100(1-3):342-8.
37. Douglas KS, Guy LS, Reeves KA, Weir J. HCR-20 violence risk assessment scheme: Overview and annotated bibliography. 2005. Implementation Science and Practice Advances Research Center Publications. 335.
38. Sachs GS, Gaulin BD, Gutierrez-Esteinou R, McQuade RD, Pikalov A, 3rd, Pultz JA, et al. Antimanic response to aripiprazole in bipolar I disorder patients is independent of the agitation level at baseline. J Clin Psychiatry. 2007;68(9):1377-83.
39. Currier GW, Citrome LL, Zimbroff DL, Oren D, Manos G, McQuade R, et al. Intramuscular aripiprazole in the control of agitation. J Psychiatr Pract. 2007;13(3):159-69.
40. Marder SR, West B, Lau GS, Pultz JA, Pikalov A, Marcus RN, et al. Aripiprazole effects in patients with acute schizophrenia experiencing higher or lower agitation: a post hoc analysis of 4 randomized, placebo-controlled clinical trials. J Clin Psychiatry. 2007;68(5):662-8.
41. Chaichan W. Evaluation of the use of the positive and negative syndrome scale-excited component as a criterion for administration of p.r.n. medication. J Psychiatr Pract. 2008;14(2):105-13.
42. Holloman GH, Jr., Zeller SL. Overview of Project BETA: Best practices in Evaluation and Treatment of Agitation. West J Emerg Med. 2012;13(1):1-2.
43. Richardson SK, Grainger PC, Ardagh MW, Morrison R. Violence and aggression in the emergency department is under-reported and under-appreciated. N Z Med J. 2018;131(1476):50-8.
44. Huckshorn KA. Re-designing state mental health policy to prevent the use of seclusion and restraint. Adm Policy Ment Health. 2006;33(4):482-91.
45. Knox DK, Holloman GH, Jr. Use and avoidance of seclusion and restraint: consensus statement of the american association for emergency psychiatry project Beta seclusion and restraint workgroup. West J Emerg Med. 2012;13(1):35-40.
46. Battaglia J. Pharmacological management of acute agitation. Drugs. 2005;65(9):1207-22.
47. MacDonald K, Wilson MP, Minassian A, Vilke GM, Perez R, Cobb P, et al. A retrospective analysis of intramuscular haloperidol and intramuscular olanzapine in the treatment of agitation in drug- and alcohol-using patients. Gen Hosp Psychiatry. 2010;32(4):443-5.
48. Vilke GM, Wilson MP, Lovecchio F. Agitation: what every emergency physician should know. Emerg Med Rep. 2009;30(19):233-43.
49. Pourshaikhian M, Abolghasem Gorji H, Aryankhesal A, Khorasani-Zavareh D, Barati A. A Systematic Literature Review: Workplace Violence Against Emergency Medical Services Personnel. Arch Trauma Res. 2016;5(1):e28734.
50. Petit JR. Management of the acutely violent patient. Psychiatr Clin North Am. 2005;28(3):701-11, 710.
51. Marco CA, Vaughan J. Emergency management of agitation in schizophrenia. Am J Emerg Med. 2005;23(6):767-76.
52. Peluso MJ, Lewis SW, Barnes TR, Jones PB. Extrapyramidal motor side-effects of first- and second-generation antipsychotic drugs. Br J Psychiatry. 2012;200(5):387-92.
53. Jibson MD. First-generation antipsychotic medications: Pharmacology, administration, and comparative side effects. UptoDate Waltham, MA(Accessed June 17, 2014). 2014.
54. Gao K, Kemp DE, Ganocy SJ, Gajwani P, Xia G, Calabrese JR. Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review. J Clin Psychopharmacol. 2008;28(2):203-9.
55. Leucht S, Cipriani A, Spineli L, Mavridis D, Örey D, Richter F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951-62.
56. Baldacara L, Sanches M, Cordeiro DC, Jackoswski AP. Rapid tranquilization for agitated patients in emergency psychiatric rooms: a randomized trial of olanzapine, ziprasidone, haloperidol plus promethazine, haloperidol plus midazolam and haloperidol alone. Braz J Psychiatry. 2011;33(1):30-9.
57. Mantovani C, Migon MN, Alheira FV, Del-Ben CM. Management of the violent or agitated patient. Braz J Psychiatry. 2010;32 Suppl 2:S96-103.
58. Wilson MP, MacDonald K, Vilke GM, Feifel D. A comparison of the safety of olanzapine and haloperidol in combination with benzodiazepines in emergency department patients with acute agitation. J Emerg Med. 2012;43(5):790-7.
59. Huf G, Coutinho ES, Adams CE. Haloperidol plus promethazine for agitated patients--a systematic review. Braz J Psychiatry. 2009;31(3):265-70.
60. Food U, Administration D. Information for healthcare professionals: haloperidol (marketed as Haldol, Haldol Decanoate and Haldol Lactate). US Food and Drug Administration Rockville, MD. 2007.
61. Meyer-Massetti C, Cheng CM, Sharpe BA, Meier CR, Guglielmo BJ. The FDA extended warning for intravenous haloperidol and torsades de pointes: how should institutions respond? J Hosp Med. 2010;5(4):E8-16.
62. Zemrak WR, Kenna GA. Association of antipsychotic and antidepressant drugs with Q-T interval prolongation. Am J Health Syst Pharm. 2008;65(11):1029-38.
63. Li M, Liz GR. Drug-Induced QT Prolongation And Torsades de Pointes. P T. 2017;42(7): 473-7.
64. Alvarez PA, Pahissa J. QT alterations in psychopharmacology: proven candidates and suspects. Curr Drug Saf. 2010;5(1):97-104.
65. Muzyk AJ, Rayfield A, Revollo JY, Heinz H, Gagliardi JP. Examination of baseline risk factors for QTc interval prolongation in patients prescribed intravenous haloperidol. Drug Saf. 2012;35(7):547-53.
66. Lopez-Munoz F, Alamo C, Cuenca E, Shen WW, Clervoy P, Rubio G. History of the discovery and clinical introduction of chlorpromazine. Ann Clin Psychiatry. 2005;17(3):113-35.
67. Turner T. Chlorpromazine: unlocking psychosis. BMJ. 2007;334 Suppl 1:s7.
68. Excellence NIfC. The short-term management of disturbed/violent behaviour in in-patient psychiatric settings and emergency departments. London: NICE. 2005.
69. Ahmed U, Jones H, Adams CE. Chlorpromazine for psychosis induced aggression or agitation. Cochrane Database Syst Rev. 2010(4):Cd007445.
70. Haro JM, Salvador-Carulla L. The SOHO (Schizophrenia Outpatient Health Outcome) study: implications for the treatment of schizophrenia. CNS drugs. 2006;20(4):293-301.
71. Ucok A, Gaebel W. Side effects of atypical antipsychotics: a brief overview. World psychiatry. 2008;7(1):58-62.
72. Kroken RA, Johnsen E, Ruud T, Wentzel-Larsen T, Jorgensen HA. Treatment of schizophrenia with antipsychotics in Norwegian emergency wards, a cross-sectional national study. BMC psychiatry. 2009;9:24.
73. Marder SR. A review of agitation in mental illness: treatment guidelines and current therapies. The J Clin Psychiatry. 2006;67 Suppl 10:13-21.
74. Zeller SL, Rhoades RW. Systematic reviews of assessment measures and pharmacologic treatments for agitation. Clin Ther. 2010;32(3):403-25.
75. Ray WA, Chung CP, Murray KT, Hall K, Stein CM. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med. 2009;360(3):225-35.
76. Oliveira IR, Nunes PM, Coutinho DM, Sena EP. Review of the efficacy of placebo in comparative clinical trials between typical and atypical antipsychotics. Braz J Psychiatry. 2009;31(1):52-6.
77. Brook S, Walden J, Benattia I, Siu CO, Romano SJ. Ziprasidone and haloperidol in the treatment of acute exacerbation of schizophrenia and schizoaffective disorder: comparison of intramuscular and oral formulations in a 6-week, randomized, blinded-assessment study. Psychopharmacology. 2005;178(4):514-23.
78. Satterthwaite TD, Wolf DH, Rosenheck RA, Gur RE, Caroff SN. A meta-analysis of the risk of acute extrapyramidal symptoms with intramuscular antipsychotics for the treatment of agitation. J Clin Psychiatry. 2008;69(12):1869-79.
79. Andrezina R, Josiassen RC, Marcus RN, Oren DA, Manos G, Stock E, et al. Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol. Psychopharmacology. 2006;188(3):281-92.
80. Raveendran NS, Tharyan P, Alexander J, Adams CE. Rapid tranquillisation in psychiatric emergency settings in India: pragmatic randomised controlled trial of intramuscular olanzapine versus intramuscular haloperidol plus promethazine. BMJ. 2007;335(7625):865.
81. Newcomer JW. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin Psychiatry. 2007;68 Suppl 1:20-7.
82. Gaebel W, Weinmann S, Sartorius N, Rutz W, McIntyre JS. Schizophrenia practice guidelines: international survey and comparison. Br J Psychiatry. 2005;187:248-55.
83. Tandon R, Belmaker RH, Gattaz WF, Lopez-Ibor JJ, Jr., Okasha A, Singh B, et al. World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. Schizophr Res. 2008;100(1-3):20-38.
84. Centorrino F, Meyers AL, Ahl J, Cincotta SL, Zun L, Gulliver AH, et al. An observational study of the effectiveness and safety of intramuscular olanzapine in the treatment of acute agitation in patients with bipolar mania or schizophrenia/schizoaffective disorder. Hum Psychopharmacol. 2007;22(7):455-62.
85. Damsa C, Adam E, Lazignac C, De Gregorio F, Mihai A, Lejeune J, et al. Intramuscular olanzapine in patients with schizophrenia: an observational study in an emergency room. Bull Soc Sci Med Grand Duche Luxemb. 2008(2):209-16.
86. Jangro WC, Preval H, Southard R, Klotz SG, Francis A. Conventional intramuscular sedatives versus ziprasidone for severe agitation in adolescents: case-control study. Child Adolesc Psychiatry Ment Health. 2009;3(1):9.
87. Kohen I, Preval H, Southard R, Francis A. Naturalistic study of intramuscular ziprasidone versus conventional agents in agitated elderly patients: retrospective findings from a psychiatric emergency service. Am J Geriatr Pharmacother. 2005;3(4):240-5.
88. Martel M, Sterzinger A, Miner J, Clinton J, Biros M. Management of acute undifferentiated agitation in the emergency department: a randomized double-blind trial of droperidol, ziprasidone, and midazolam. Acad Emerg Med. 2005;12(12):1167-72.
89. Preval H, Klotz SG, Southard R, Francis A. Rapid-acting IM ziprasidone in a psychiatric emergency service: a naturalistic study. Gen Hosp Psychiatry. 2005;27(2):140-4.
90. San L, Arranz B, Querejeta I, Barrio S, De la Gandara J, Perez V. A naturalistic multicenter study of intramuscular olanzapine in the treatment of acutely agitated manic or schizophrenic patients. Eur Psychiatry. 2006;21(8):539-43.
91. Veser FH, Veser BD, McMullan JT, Zealberg J, Currier GW. Risperidone versus haloperidol, in combination with lorazepam, in the treatment of acute agitation and psychosis: a pilot, randomized, double-blind, placebo-controlled trial. J Psychiatr Pract. 2006;12(2):103-8.
92. Zimbroff DL, Marcus RN, Manos G, Stock E, McQuade RD, Auby P, et al. Management of acute agitation in patients with bipolar disorder: efficacy and safety of intramuscular aripiprazole. J Clin Psychopharmacol. 2007;27(2):171-6.
93. Tran-Johnson TK, Sack DA, Marcus RN, Auby P, McQuade RD, Oren DA. Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2007;68(1):111-9.
94. Scherk H, Pajonk FG, Leucht S. Second-generation antipsychotic agents in the treatment of acute mania: a systematic review and meta-analysis of randomized controlled trials. Arch Gen Psychiatry. 2007;64(4):442-55.
95. Smith LA, Cornelius V, Warnock A, Tacchi MJ, Taylor D. Pharmacological interventions for acute bipolar mania: a systematic review of randomized placebo-controlled trials. Bipolar Disord. 2007;9(6):551-60.
96. Hsu WY, Huang SS, Lee BS, Chiu NY. Comparison of intramuscular olanzapine, orally disintegrating olanzapine tablets, oral risperidone solution, and intramuscular haloperidol in the management of acute agitation in an acute care psychiatric ward in Taiwan. J Clin Psychopharmacol. 2010;30(3):230-4.
97. Hatta K, Kawabata T, Yoshida K, Hamakawa H, Wakejima T, Furuta K, et al. Olanzapine orally disintegrating tablet vs. risperidone oral solution in the treatment of acutely agitated psychotic patients. Gen Hosp Psychiatry. 2008;30(4):367-71.
98. Lim HK, Kim JJ, Pae CU, Lee CU, Lee C, Paik IH. Comparison of risperidone orodispersible tablet and intramuscular haloperidol in the treatment of acute psychotic agitation: a randomized open, prospective study. Neuropsychobiology. 2010;62(2):81-6.
99. Villari V, Rocca P, Fonzo V, Montemagni C, Pandullo P, Bogetto F. Oral risperidone, olanzapine and quetiapine versus haloperidol in psychotic agitation. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(2):405-13.
100. Hovens JE, Dries PJ, Melman CT, Wapenaar RJ, Loonen AJ. Oral risperidone with lorazepam versus oral zuclopenthixol with lorazepam in the treatment of acute psychosis in emergency psychiatry: a prospective, comparative, open-label study. J Psychopharmacol. 2005;19(1):51-7.
101. Pascual JC, Perez V, Martin JL, Safont G, Puigdemont D, Alvarez E. Olanzapine orally-disintegrating tablet in severe psychotic agitation: a naturalistic study. Actas Esp Psiquiatr. 2007;35(1):47-51.
102. Citrome L. Comparison of intramuscular ziprasidone, olanzapine, or aripiprazole for agitation: a quantitative review of efficacy and safety. J Clin Psychiatry. 2007;68(12):1876-85.
103. Mohr P, Pecenak J, Svestka J, Swingler D, Treuer T. Treatment of acute agitation in psychotic disorders. Neuro Endocrinol Lett. 2005;26(4):327-35.
104. Castle DJ, Udristoiu T, Kim CY, Sarosi A, Pidrman V, Omar AN, et al. Intramuscular olanzapine versus short-acting typical intramuscular antipsychotics: comparison of real-life effectiveness in the treatment of agitation. World J Biol Psychiatry. 2009;10(1):43-53.
105. Green AI, Lieberman JA, Hamer RM, Glick ID, Gur RE, Kahn RS, et al. Olanzapine and haloperidol in first episode psychosis: two-year data. Schizophr Res. 2006;86(1-3):234-43.
106. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373(9657):31-41.
107. Belgamwar RB, Fenton M. Olanzapine IM or velotab for acutely disturbed/agitated people with suspected serious mental illnesses. Cochrane Database Syst Rev. 2005(2):Cd003729.
108. Kinon BJ, Stauffer VL, Kollack-Walker S, Chen L, Sniadecki J. Olanzapine versus aripiprazole for the treatment of agitation in acutely ill patients with schizophrenia. J Clin Psychopharmacol. 2008;28(6):601-7.
109. Marder SR, Sorsaburu S, Dunayevich E, Karagianis JL, Dawe IC, Falk DM, et al. Case reports of postmarketing adverse event experiences with olanzapine intramuscular treatment in patients with agitation. J Clin Psychiatry. 2010;71(4):433-41.
110. Lonergan E, Britton AM, Luxenberg J, Wyller T. Antipsychotics for delirium. Cochrane Database Syst Rev. 2007(2):Cd005594.
111. Lilly E. Zyprexa (olanzapine) package insert. Indianapolis, IN. 2005.
112. Zacher JL, Roche-Desilets J. Hypotension secondary to the combination of intramuscular olanzapine and intramuscular lorazepam. J Clin Psychiatry. 2005;66(12):1614-5.
113. Smith MA, McCoy R, Hamer-Maansson J, Brecher M. Rapid dose escalation with quetiapine: a pilot study. J Clin Psychopharmacol. 2005;25(4):331-5.
114. Currier GW, Trenton AJ, Walsh PG, van Wijngaarden E. A pilot, open-label safety study of quetiapine for treatment of moderate psychotic agitation in the emergency setting. J Psychiatr Pract. 2006;12(4):223-8.
115. Warrington L, Lombardo I, Loebel A, Ice K. Ziprasidone for the treatment of acute manic or mixed episodes associated with bipolar disorder. CNS drugs. 2007;21(10):835-49.
116. Zimbroff DL, Allen MH, Battaglia J, Citrome L, Fishkind A, Francis A, et al. Best clinical practice with ziprasidone IM: update after 2 years of experience. CNS Spectr. 2005;10(9):1-15.
117. Barzman DH, DelBello MP, Forrester JJ, Keck PE, Jr., Strakowski SM. A retrospective chart review of intramuscular ziprasidone for agitation in children and adolescents on psychiatric units: prospective studies are needed. J Child Adolesc Psychopharmacol. 2007;17(4):503-9.
118. De Filippis S, Cuomo I, Lionetto L, Janiri D, Simmaco M, Caloro M, et al. Intramuscular aripiprazole in the acute management of psychomotor agitation. Pharmacotherapy. 2013;33(6):603-14.
119. Mauri MC, Steinhilber CP, Marino R, Invernizzi E, Fiorentini A, Cerveri G, et al. Clinical outcome and olanzapine plasma levels in acute schizophrenia. Eur Psychiatry. 2005;20(1):55-60.
120. Nozawa M, Ohnuma T, Matsubara Y, Sakai Y, Hatano T, Hanzawa R, et al. The relationship between the response of clinical symptoms and plasma olanzapine concentration, based on pharmacogenetics: Juntendo University Schizophrenia Projects (JUSP). Ther Drug Monit. 2008;30(1):35-40.
121. McIntyre J, Robertson S, Norris E, Appleton R, Whitehouse WP, Phillips B, et al. Safety and efficacy of buccal midazolam versus rectal diazepam for emergency treatment of seizures in children: a randomised controlled trial. Lancet. 2005;366(9481):205-10.
122. Mehta V, Singhi P, Singhi S. Intravenous sodium valproate versus diazepam infusion for the control of refractory status epilepticus in children: a randomized controlled trial. J Child Neurol. 2007;22(10):1191-7.
123. Pellock JM, Shinnar S. Respiratory adverse events associated with diazepam rectal gel. Neurology. 2005;64(10):1768-70.
124. McMullan J, Sasson C, Pancioli A, Silbergleit R. Midazolam versus diazepam for the treatment of status epilepticus in children and young adults: a meta-analysis. Acad Emerg Med. 2010;17(6):575-82.
125. Vincent J-L, Shehabi Y, Walsh TS, Pandharipande PP, Ball JA, Spronk P, et al. Comfort and patient-centred care without excessive sedation: the eCASH concept. Intensive Care Med. 2016;42(6):962-71.
126. Rund DA, Ewing JD, Mitzel K, Votolato N. The use of intramuscular benzodiazepines and antipsychotic agents in the treatment of acute agitation or violence in the emergency department. J Emerg Med. 2006;31(3):317-24.
127. Licata SC, Platt DM, Cook JM, Van Linn ML, Rowlett JK. Contribution of alpha1 subunit-containing gamma-aminobutyric acidA (GABAA) receptors to motor-impairing effects of benzodiazepines in squirrel monkeys. Psychopharmacology. 2009;203(3):539-46.
128. Papineni A, Lourenco-Matharu L, Ashley PF. Safety of oral midazolam sedation use in paediatric dentistry: a review. Int J Paediatr Dent. 2014;24(1):2-13.
129. MacDonald K, Wilson M, Minassian A, Vilke GM, Becker O, Tallian K, et al. A naturalistic study of intramuscular haloperidol versus intramuscular olanzapine for the management of acute agitation. J Clin Psychopharmacol. 2012;32(3):317-22.
130. Gillies D, Beck A, McCloud A, Rathbone J, Gillies D. Benzodiazepines alone or in combination with antipsychotic drugs for acute psychosis. Cochrane Database Syst Rev. 2005(4):Cd003079.
131. Pacciardi B, Mauri M, Cargioli C, Belli S, Cotugno B, Di Paolo L, et al. Issues in the management of acute agitation: how much current guidelines consider safety? Front Psychiatry. 2013;4:26.
132. Arcangeli A, Antonelli M, Mignani V, Sandroni C. Sedation in PACU: the role of benzodiazepines. Curr Drug Targets. 2005;6(7):745-8.
133. Boomsma MM, Mengels O, van Olden RW. Risks associated with parenteral treatment of acute agitation. Tijdschr Psychiatr. 2006;48(2):135-9.
134. Wilson MP, MacDonald K, Vilke GM, Feifel D. Potential complications of combining intramuscular olanzapine with benzodiazepines in emergency department patients. J Emerg Med. 2012;43(5):889-96.
135. Cunha M, André S, Bica I, Ribeiro O, Dias A, Andrade A. Chemical and physical restraint of patients. Procedia Soc Behav Sci. 2016;217:389-99.
136. Leahy-Warren P, Varghese V, Day MR, Curtin M. Physical restraint: perceptions of nurse managers, registered nurses and healthcare assistants. Int Nurs Rev. 2018;65(3):327-35.
137. Gildberg FA, Fristed P, Makransky G, Moeller EH, Nielsen LD, Bradley SK. As time goes by: reasons and characteristics of prolonged episodes of mechanical restraint in forensic psychiatry. J Forensic Nurs. 2015;11(1):41-50.
138. Hui A, Middleton H, Völlm B. Coercive measures in forensic settings: Findings from the literature. Int J Forensic Ment Health. 2013;12(1):53-67.
139. Cannon M, Sprivulis P, McCarthy J. Restraint practices in Australasian emergency departments. The Aust N Z J Psychiatry. 2001;35(4):464-7.
140. Martin B, Mathisen L. Use of physical restraints in adult critical care: a bicultural study. Am J Crit Care. 2005;14(2):133-42.
141. Mason J, Colwell CB, Grock A. Agitation Crisis Control. Ann Emerg Med. 2018;72(4):371-3.
142. Coburn VA, Mycyk MB. Physical and chemical restraints. Emerg Med Clin North Am. 2009;27(4):655-67, ix.
143. Wilson EB. Physical restraint of elderly patients in critical care: historical perspectives and new directions. Crit Care Nurs Clin North Am. 1996;8(1):61-70.
144. Physicians ACoE. Use of patient restraints. Policy statement. Ann Emerg Med. 2014;64(5):574.
145. James A, Madeley R, Dove A. Violence and aggression in the emergency department. Emerg Med J. 2006;23(6):431-4.
146. Pich J, Hazelton M, Sundin D, Kable A. Patient-related violence at triage: A qualitative descriptive study. Int Emerg Nurs. 2011;19(1):12-9.
147. Baskin-Sommers A, Sommers I. Methamphetamine Use and Violence Among Young Adults. J Crim Justice 2006;34(6):661-74.
148. Holleran RS. Preventing staff injuries from violence. J Emerg Nurs. 2006;32(6):523-4.
149. Gates D, Ross C, McQueen L. Violence: Recognition, management and prevention. J Emerg Med. 2005;31(3):331-7.
150. Landau SF, Bendalak Y. Personnel exposure to violence in hospital emergency wards: a routine activity approach. Aggress Behav. 2008;34(1):88-103.
151. Gilchrist H, Jones SC, Barrie L. Experiences of emergency department staff: Alcohol-related and other violence and aggression. Australas Emerg Nurs J. 2011;14(1):9-16.
152. Gillespie GL, Gates DM, Miller M, Howard PK. Emergency department workers' perceptions of security officers' effectiveness during violent events. Work. 2012;42(1):21-7.
153. Wand TC, Coulson K. Zero tolerance: a policy in conflict with current opinion on aggression and violence management in health care. Australas Emerg Nurs J. 2006;9(4):163-70.
154. Mackay I, Paterson B, Cassells C. Constant or special observations of inpatients presenting a risk of aggression or violence: nurses' perceptions of the rules of engagement. J Psychiatr Ment Health Nurs. 2005;12(4):464-71.
155. Ramacciati N, Ceccagnoli A, Addey B, Rasero L. Violence towards Emergency Nurses. The Italian National Survey 2016: A qualitative study. Int J Nurs Stud. 2018;81:21-9.
156. Allen MH, Currier GW, Carpenter D, Ross RW, Docherty JP. The expert consensus guideline series. Treatment of behavioral emergencies 2005. J Psychiatr Pract. 2005;11 Suppl 1:5-108; quiz 10-2.
157. Currier GW. The controversy over "chemical restraint" in acute care psychiatry. J Psychiatr Pract. 2003;9(1):59-70.
158. Hopper AB, Vilke GM, Castillo EM, Campillo A, Davie T, Wilson MP. Ketamine use for acute agitation in the emergency department. J Emerg Med. 2015;48(6):712-9.
159. Alexopoulos GS, Streim J, Carpenter D, Docherty JP. Using antipsychotic agents in older patients. J Clin Psychiatry. 2004;65 Suppl 2:5-99; discussion 100-2; quiz 3-4.
160. Gerson R, Malas N, Mroczkowski MM. Crisis in the Emergency Department: The Evaluation and Management of Acute Agitation in Children and Adolescents. Child Adolesc Psychiatr Clin N Am. 2018;27(3):367-86.
161. Vieta E, Garriga M, Cardete L, Bernardo M, Lombrana M, Blanch J, et al. Protocol for the management of psychiatric patients with psychomotor agitation. BMC psychiatry. 2017;17(1):328.
162. Larue C, Dumais A, Ahern E, Bernheim E, Mailhot MP. Factors influencing decisions on seclusion and restraint. J Psychiatr Ment Health Nurs. 2009;16(5):440-6.
163. Farina-Lopez E, Estevez-Guerra GJ, Polo-Luque ML, Hanzelikova Pogranyiva A, Penelo E. Physical Restraint Use With Elderly Patients: Perceptions of Nurses and Nursing Assistants in Spanish Acute Care Hospitals. Nurs Res. 2018;67(1):55-9.
164. Laiho T, Kattainen E, Astedt-Kurki P, Putkonen H, Lindberg N, Kylma J. Clinical decision making involved in secluding and restraining an adult psychiatric patient: an integrative literature review. J Psychiatr Ment Health Nurs. 2013;20(9):830-9.
165. Kallert TW. Involuntary psychiatric hospitalization: current status and future prospects. Srp Arh Celok Lek. 2011;139 Suppl 1:14-20.
166. Hodge AN, Marshall AP. Violence and aggression in the emergency department: a critical care perspective. Aust Crit Care. 2007;20(2):61-7.
167. Perkins E, Prosser H, Riley D, Whittington R. Physical restraint in a therapeutic setting; a necessary evil? Int J Law Psychiatry. 2012;35(1):43-9.
168. De Hert M, Einfinger G, Scherpenberg E, Wampers M, Peuskens J. The prevention of deep venous thrombosis in physically restrained patients with schizophrenia. Int J Clin Pract. 2010;64(8):1109-15.
169. Maly R, Masopust J, Hosak L, Konupcikova K. Assessment of risk of venous thromboembolism and its possible prevention in psychiatric patients. Psychiatry Clin Neurosci. 2008;62(1):3-8.
170. Steinert T, Lepping P, Bernhardsgrutter R, Conca A, Hatling T, Janssen W, et al. Incidence of seclusion and restraint in psychiatric hospitals: a literature review and survey of international trends. Soc Psychiatry Psychiatr Epidemiol. 2010;45(9):889-97.
171. Cecchi R, Lazzaro A, Catanese M, Mandarelli G, Ferracuti S. Fatal thromboembolism following physical restraint in a patient with schizophrenia. Int J Legal Med. 2012;126(3):477-82.
172. Dickson BC, Pollanen MS. Fatal thromboembolic disease: a risk in physically restrained psychiatric patients. J Forensic Leg Med. 2009;16(5):284-6.
173. Ishida T, Katagiri T, Uchida H, Takeuchi H, Sakurai H, Watanabe K, et al. Incidence of deep vein thrombosis in restrained psychiatric patients. Psychosomatics. 2014;55(1):69-75.
174. Karger B, Fracasso T, Pfeiffer H. Fatalities related to medical restraint devices-asphyxia is a common finding. Forensic Sci Int. 2008;178(2-3):178-84.
175. Laursen SB, Jensen TN, Bolwig T, Olsen NV. Deep venous thrombosis and pulmonary embolism following physical restraint. Acta Psychiatr Scand. 2005;111(4):324-7; discussion 7.
176. Rakhmatullina M, Taub A, Jacob T. Morbidity and mortality associated with the utilization of restraints : a review of literature. Psychiatr Q. 2013;84(4):499-512.
177. Cowman S, Bjorkdahl A, Clarke E, Gethin G, Maguire J. A descriptive survey study of violence management and priorities among psychiatric staff in mental health services, across seventeen european countries. BMC Health Serv Res. 2017;17(1):59.
178. Nelstrop L, Chandler-Oatts J, Bingley W, Bleetman T, Corr F, Cronin-Davis J, et al. A systematic review of the safety and effectiveness of restraint and seclusion as interventions for the short-term management of violence in adult psychiatric inpatient settings and emergency departments. Worldviews Evid Based Nurs. 2006;3(1):8-18.
179. Paterson B, McIntosh I, Wilkinson D, McComish S, Smith I. Corrupted cultures in mental health inpatient settings. Is restraint reduction the answer? J Psychiatr Ment Health Nurs. 2013;20(3):228-35.
180. An FR, Sha S, Zhang QE, Ungvari GS, Ng CH, Chiu HF, et al. Physical restraint for psychiatric patients and its associations with clinical characteristics and the National Mental Health Law in China. Psychiatry Res. 2016;241:154-8.
181. Steinert T, Lepping P. Legal provisions and practice in the management of violent patients. a case vignette study in 16 European countries. Eur Psychiatry. 2009;24(2):135-41.
182. Azeem MW, Aujla A, Rammerth M, Binsfeld G, Jones RB. Effectiveness of six core strategies based on trauma informed care in reducing seclusions and restraints at a child and adolescent psychiatric hospital. J Child Adolesc Psychiatr Nurs. 2011;24(1):11-5.
183. Hellerstein DJ, Staub AB, Lequesne E. Decreasing the use of restraint and seclusion among psychiatric inpatients. J Psychiatr Pract. 2007;13(5):308-17.
184. Martin A, Krieg H, Esposito F, Stubbe D, Cardona L. Reduction of restraint and seclusion through collaborative problem solving: a five-year prospective inpatient study. Psychiatr Serv. 2008;59(12):1406-12.
185. Currier GW, Walsh P, Lawrence D. Physical restraints in the emergency department and attendance at subsequent outpatient psychiatric treatment. J Psychiatr Pract. 2011;17(6):387-93.
186. Demir A. Nurses' use of physical restraints in four Turkish hospitals. J Nurs Scholarsh. 2007;39(1):38-45.
187. Downes MA, Healy P, Page CB, Bryant JL, Isbister GK. Structured team approach to the agitated patient in the emergency department. Emerg Med Australas. 2009;21(3):196-202.
188. Dumais A, Larue C, Drapeau A, Menard G, Giguere Allard M. Prevalence and correlates of seclusion with or without restraint in a Canadian psychiatric hospital: a 2-year retrospective audit. J Psychiatr Ment Health Nurs. 2011;18(5):394-402.
189. Lane C, Harrington A. The factors that influence nurses' use of physical restraint: A thematic literature review. Int J Nurs Prac. 2011;17(2):195-204.
190. Gelkopf M, Roffe Z, Behrbalk P, Melamed Y, Werbloff N, Bleich A. Attitudes, opinions, behaviors, and emotions of the nursing staff toward patient restraint. Issues Ment Health Nurs. 2009;30(12):758-63.
191. Gerace A, Pamungkas DR, Oster C, Thomson D, Muir-Cochrane E. The use of restraint in four general hospital emergency departments in Australia. Australas Psychiatry. 2014;22(4):366-9.
192. Raboch J, Kalisova L, Nawka A, Kitzlerova E, Onchev G, Karastergiou A, et al. Use of coercive measures during involuntary hospitalization: findings from ten European countries. Psychiatr Serv. 2010;61(10):1012-7.
193. Knutzen M, Sandvik L, Hauff E, Opjordsmoen S, Friis S. Association between patients' gender, age and immigrant background and use of restraint--a 2-year retrospective study at a department of emergency psychiatry. Nord J Psychiatry. 2007;61(3):201-6.
194. Knutzen M, Bjorkly S, Eidhammer G, Lorentzen S, Helen Mjosund N, Opjordsmoen S, et al. Mechanical and pharmacological restraints in acute psychiatric wards--why and how are they used? Psychiatry Res. 2013;209(1):91-7.
195. Knutzen M, Bjorkly S, Eidhammer G, Lorentzen S, Mjosund NH, Opjordsmoen S, et al. Characteristics of patients frequently subjected to pharmacological and mechanical restraint--a register study in three Norwegian acute psychiatric wards. Psychiatry Res. 2014;215(1):127-33.
196. Kontio R, Joffe G, Putkonen H, Kuosmanen L, Hane K, Holi M, et al. Seclusion and restraint in psychiatry: patients' experiences and practical suggestions on how to improve practices and use alternatives. Perspect Psychiatr Care. 2012;48(1):16-24.
197. Mayers P, Keet N, Winkler G, Flisher AJ. Mental health service users' perceptions and experiences of sedation, seclusion and restraint. Int J Soc Psychiatry. 2010;56(1):60-73.
198. McCurdy JM, Haliburton JR, Yadav HC, Yoder AM, Norton LR, Froehlich JA, et al. Case study: design may influence use of seclusion and restraint. Herd. 2015;8(3):116-21.
199. Migon MN, Coutinho ES, Huf G, Adams CE, Cunha GM, Allen MH. Factors associated with the use of physical restraints for agitated patients in psychiatric emergency rooms. Gen Hosp Psychiatry. 2008;30(3):263-8.
200. Khatib A, Ibrahim M, Roe D. Re-building Trust after Physical Restraint During Involuntary Psychiatric Hospitalization. Arch Psychiatr Nurs. 2018;32(3):457-61.
| Files | ||
| Issue | Vol 3 No 1 (2019): Winter (February) | |
| Section | Review article | |
| PMCID | PMC6548084 | |
| PMID | 31172118 | |
| Keywords | ||
| Aggression Emergency Service, Hospital Restraint, Physical Violence | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
How to Cite
1.
Ziaei M, Massoudifar A, Rajabpour-Sanati A, Pourbagher-Shahri A-M, Abdolrazaghnejad A. Management of Violence and Aggression in Emergency Environment; a Narrative Review of 200 Related Articles. Front Emerg Med. 2018;3(1):e7.
Downloads
Download data is not yet available.
